| Literature DB >> 32148955 |
Amani Alnimr1, Aisha Alamri2, Afnan Alsultan2.
Abstract
Introduction. Imipenem-resistant Acinetobacter baumannii (IRAB) represents a major clinical threat. Dissemination in critical care areas necessitates effective action measures including genotyping tools to study the clonality of these strains and trace their origin. The main aim of this study is to assess the genetic relatedness between IRAB isolates in our institution intensive care units (ICU) which are at a particular risk of outbreaks.Entities:
Year: 2020 PMID: 32148955 PMCID: PMC7054769 DOI: 10.1155/2020/3290316
Source DB: PubMed Journal: Crit Care Res Pract ISSN: 2090-1305
Characteristics of critically ill patients from whom the carbapenem-resistant A. baumannii was isolated. The frequency of isolation showed an increasing trend with age.
| No (%) | |
|---|---|
| Colonization | 31 (38.8) |
| Infection | 49 (61.2) |
| Males | 42 (52.5) |
| Females | 38 (47.5) |
| Age in years | |
| <15 | 1 (1.2) |
| 15–44 | 20 (25) |
| 45–64 | 27 (33.8) |
| ≥65 | 32 (40) |
| Medical ICU | 53 (66.3) |
| Surgical ICU | 27 (33.7) |
| 30 days crude mortality | 15 (18.8) |
30 days crude mortality from 13 cases of blood stream infections by carbapenem-resistant A. baumannii was 61.5%.
Distribution of clinical isolates according to sample type and year in the intensive care units over the study period.
| Year | 2016 | 2017 | 2018 | Total |
|---|---|---|---|---|
| Respiratory | 4 | 37 | 21 | 62 |
| Blood | 2 | 9 | 2 | 13 |
| Skin/soft tissues | 1 | 1 | 1 | 3 |
| Others | 1 | 1 | 0 | 2 |
| Total | 8 | 48 | 24 | 80 |
Susceptibility profiles of 80 strains of carbapenem-resistant A. baumannii isolated from intensive care cases.
| Antimicrobial | Susceptibility rates % |
|---|---|
| Ceftazidime | 0 |
| Cefepime | 0 |
| Piperacillin-tazobactam | 0 |
| Imipenem | 0 |
| Meropenem | 43.8 |
| Gentamicin | 53.8 |
| Amikacin | 53.8 |
| Ciprofloxacin | 0 |
| Levofloxacin | 5 |
| Trimethoprim-sulfamethoxazole | 8.8 |
Susceptibility profiles of 13 strains of carbapenem-resistant A. baumannii isolated from blood stream infections in the intensive care. MIC ranges for meropenem 1–256 µg/ml.
| Antimicrobial | Susceptibility rates % |
|---|---|
| Ceftazidime | 0 |
| Cefepime | 0 |
| Piperacillin-tazobactam | 0 |
| Imipenem | 0 |
| Meropenem | 46.2 |
| Gentamicin | 46.2 |
| Amikacin | 46.2 |
| Ciprofloxacin | 0 |
| Levofloxacin | 7.7 |
| Trimethoprim-sulfamethoxazole | 23.1 |
Minimal inhibitory concentrations of tigecycline against 80 strains of carbapenem-resistant Acinetobacter baumannii (MIC50 = 2 µg/ml, MIC90 = 4 µg/ml). Tigecycline susceptible strains represented 53.8% of the complete cohort.
| MIC ( | No. of isolates (%) | Cumulative no. of isolates (%) |
|---|---|---|
| 1 | 12 (15) | 12 (15) |
| 2 | 31 (38.8) | 43 (53.8) |
| 3 | 26 (32.5) | 69 (86.3) |
| 4 | 4 (5) | 73 (91.3) |
| 6 | 1 (1.3) | 74 (92.5) |
| 8 | 2 (2.5) | 76 (95) |
| 16 | 3 (3.8) | 79 (98.8) |
| 32 | 1 (1.3) | 80 (100) |
Figure 1Dendrogram showing genetic diversity of 80 carbapenem-resistant Acinetobacter baumannii isolated from patients admitted to intensive care units between 2016 and 2018 typed by enterobacterial repetitive intergenic consensus‐polymerase chain reaction with the numbers indicating the corresponding strains followed by meropenem susceptibility status.